Srinivasan Ramanathan

Summary

Affiliation: Gilead Sciences
Country: USA

Publications

  1. ncbi Absence of clinically relevant pharmacokinetic interaction between ribavirin and tenofovir in healthy subjects
    Srinivasan Ramanathan
    Gilead Sciences Inc, Foster City, CA 94404, USA
    J Clin Pharmacol 46:559-66. 2006
  2. ncbi Pharmacokinetics of emtricitabine, tenofovir, and GS-9137 following coadministration of emtricitabine/tenofovir disoproxil fumarate and ritonavir-boosted GS-9137
    Srinivasan Ramanathan
    Gilead Sciences, Inc, Foster City, CA 94404, USA
    J Acquir Immune Defic Syndr 45:274-9. 2007
  3. ncbi Pharmacokinetics of coadministered ritonavir-boosted elvitegravir and zidovudine, didanosine, stavudine, or abacavir
    Srinivasan Ramanathan
    Gilead Sciences, Foster City, CA 94404, USA
    J Acquir Immune Defic Syndr 46:160-6. 2007
  4. ncbi Pharmacokinetics of elvitegravir and etravirine following coadministration of ritonavir-boosted elvitegravir and etravirine
    Srinivasan Ramanathan
    Gilead Sciences, Inc, Foster City, CA, USA
    Antivir Ther 13:1011-7. 2008
  5. ncbi Pharmacokinetic interaction of ritonavir-boosted elvitegravir and maraviroc
    Srinivasan Ramanathan
    Gilead Sciences, Inc, Foster City, CA 94404, USA
    J Acquir Immune Defic Syndr 53:209-14. 2010
  6. ncbi Systemic and renal pharmacokinetics of adefovir and tenofovir upon coadministration
    Brian P Kearney
    Gilead Sciences Inc, 333 Lakeside Drive, Foster City, CA 94404, USA
    J Clin Pharmacol 45:935-40. 2005
  7. ncbi Clinical pharmacokinetic and pharmacodynamic profile of the HIV integrase inhibitor elvitegravir
    Srinivasan Ramanathan
    Gilead Sciences, Inc, Foster City, California 94404, USA
    Clin Pharmacokinet 50:229-44. 2011
  8. ncbi Randomized, phase 2 evaluation of two single-tablet regimens elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate versus efavirenz/emtricitabine/tenofovir disoproxil fumarate for the initial treatment of HIV infection
    Calvin Cohen
    Gilead Sciences Inc, Foster City, California, USA
    AIDS 25:F7-12. 2011

Detail Information

Publications8

  1. ncbi Absence of clinically relevant pharmacokinetic interaction between ribavirin and tenofovir in healthy subjects
    Srinivasan Ramanathan
    Gilead Sciences Inc, Foster City, CA 94404, USA
    J Clin Pharmacol 46:559-66. 2006
    ..These results indicate that coadministration of tenofovir disoproxil fumarate and ribavirin does not result in substantial changes to their individual pharmacokinetic profiles...
  2. ncbi Pharmacokinetics of emtricitabine, tenofovir, and GS-9137 following coadministration of emtricitabine/tenofovir disoproxil fumarate and ritonavir-boosted GS-9137
    Srinivasan Ramanathan
    Gilead Sciences, Inc, Foster City, CA 94404, USA
    J Acquir Immune Defic Syndr 45:274-9. 2007
    ..To evaluate the potential for clinically relevant drug-drug interaction between emtricitabine/tenofovir disoproxil fumarate (FTC/TDF) and the ritonavir-boosted HIV integrase inhibitor GS-9137 (GS-9137/r)...
  3. ncbi Pharmacokinetics of coadministered ritonavir-boosted elvitegravir and zidovudine, didanosine, stavudine, or abacavir
    Srinivasan Ramanathan
    Gilead Sciences, Foster City, CA 94404, USA
    J Acquir Immune Defic Syndr 46:160-6. 2007
    ....
  4. ncbi Pharmacokinetics of elvitegravir and etravirine following coadministration of ritonavir-boosted elvitegravir and etravirine
    Srinivasan Ramanathan
    Gilead Sciences, Inc, Foster City, CA, USA
    Antivir Ther 13:1011-7. 2008
    ....
  5. ncbi Pharmacokinetic interaction of ritonavir-boosted elvitegravir and maraviroc
    Srinivasan Ramanathan
    Gilead Sciences, Inc, Foster City, CA 94404, USA
    J Acquir Immune Defic Syndr 53:209-14. 2010
    ..The pharmacokinetic (PK) interaction between ritonavir-boosted elvitegravir (elvitegravir/r) and maraviroc was evaluated...
  6. ncbi Systemic and renal pharmacokinetics of adefovir and tenofovir upon coadministration
    Brian P Kearney
    Gilead Sciences Inc, 333 Lakeside Drive, Foster City, CA 94404, USA
    J Clin Pharmacol 45:935-40. 2005
    ..These results demonstrate that coadministration of tenofovir disoproxil fumarate and adefovir dipivoxil does not result in substantial changes to their individual pharmacokinetic profiles...
  7. ncbi Clinical pharmacokinetic and pharmacodynamic profile of the HIV integrase inhibitor elvitegravir
    Srinivasan Ramanathan
    Gilead Sciences, Inc, Foster City, California 94404, USA
    Clin Pharmacokinet 50:229-44. 2011
    ....
  8. ncbi Randomized, phase 2 evaluation of two single-tablet regimens elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate versus efavirenz/emtricitabine/tenofovir disoproxil fumarate for the initial treatment of HIV infection
    Calvin Cohen
    Gilead Sciences Inc, Foster City, California, USA
    AIDS 25:F7-12. 2011
    ..To assess the safety and efficacy of two, single-tablet regimens for the initial treatment of HIV infection...